0.9842
price down icon2.07%   -0.0208
 
loading
Io Biotech Inc stock is traded at $0.9842, with a volume of 180.21K. It is down -2.07% in the last 24 hours and up +7.65% over the past month. IO Biotech Inc is a clinical-stage biopharmaceutical company developing novel, immune-modulating cancer vaccines based on T-win technology platform. The product candidates are designed to induce the immune system to simultaneously target and disrupt multiple pathways that regulate tumor-induced immunosuppression.
See More
Previous Close:
$1.005
Open:
$0.9683
24h Volume:
180.21K
Relative Volume:
1.11
Market Cap:
$64.84M
Revenue:
-
Net Income/Loss:
$-86.08M
P/E Ratio:
-0.4562
EPS:
-2.1574
Net Cash Flow:
$-72.06M
1W Performance:
-15.16%
1M Performance:
+7.65%
6M Performance:
-14.42%
1Y Performance:
-39.99%
1-Day Range:
Value
$0.927
$1.01
1-Week Range:
Value
$0.9269
$1.1986
52-Week Range:
Value
$0.66
$1.79

Io Biotech Inc Stock (IOBT) Company Profile

Name
Name
Io Biotech Inc
Name
Phone
(457) 070-2980
Name
Address
OLE MAALOES VEH 3, COPENHAGEN
Name
Employee
80
Name
Twitter
Name
Next Earnings Date
2025-03-31
Name
Latest SEC Filings
Name
IOBT's Discussions on Twitter

Compare IOBT with other stocks

Stocks Price Market Cap Revenue Net Income Cash Flow EPS
Biotechnology icon
IOBT
Io Biotech Inc
0.9842 64.84M 0 -86.08M -72.06M -2.1574
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
474.62 121.88B 11.02B -535.60M -978.00M -2.20
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
573.45 62.69B 14.20B 4.41B 3.54B 38.28
Biotechnology icon
ARGX
Argen X Se Adr
555.11 33.86B 2.19B 833.04M -1.28B 12.71
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
235.74 30.51B 2.25B -278.16M -42.59M -2.17
Biotechnology icon
ONC
Beigene Ltd Adr
238.51 25.69B 3.81B -644.79M -669.77M -6.24

Io Biotech Inc Stock (IOBT) Latest News

pulisher
Apr 02, 2025

Top 5 AI & Digital Biotech Companies (April 2025) - Securities.io

Apr 02, 2025
pulisher
Apr 02, 2025

IO Biotech (NASDAQ:IOBT) Given “Buy” Rating at HC Wainwright - Defense World

Apr 02, 2025
pulisher
Mar 27, 2025

IO Biotech secures over 400 million dkk in new capital - Dansk Industri

Mar 27, 2025
pulisher
Mar 25, 2025

IO Biotech Announces Acceptance of Abstracts to be Presented at the 2025 American Association for Cancer Research (AACR) Annual Meeting - The Manila Times

Mar 25, 2025
pulisher
Mar 25, 2025

IO Biotech Announces Acceptance Of Abstracts To Be Presented At The 2025 American Association For Cancer Research (AACR) Annual Meeting - MarketScreener

Mar 25, 2025
pulisher
Mar 25, 2025

Cancer Vaccine Breakthrough: IO Biotech Reveals Phase 3 Melanoma Data at AACR 2025 - Stock Titan

Mar 25, 2025
pulisher
Mar 25, 2025

12 Health Care Stocks Moving In Tuesday's Intraday Session - Benzinga

Mar 25, 2025
pulisher
Mar 21, 2025

Cathie Wood Goes Bargain Hunting: 3 Stocks She Just Bought - The Globe and Mail

Mar 21, 2025
pulisher
Mar 20, 2025

Why Five Below Shares Are Trading Higher By 12%; Here Are 20 Stocks Moving Premarket - Benzinga

Mar 20, 2025
pulisher
Mar 18, 2025

IO Biotech Named Among Fast Company's World's Most Innovative Companies of 2025 - The Manila Times

Mar 18, 2025
pulisher
Mar 18, 2025

IO Biotech Named Among Fast Company’s World’s Most Innovative Companies of 2025 - TradingView

Mar 18, 2025
pulisher
Mar 18, 2025

Fast Company Names IO Biotech Top 10 Innovator for Cancer Vaccine Breakthrough - StockTitan

Mar 18, 2025
pulisher
Mar 18, 2025

These 10 biotech companies are changing how we discover new drugs and treat complex diseases - Fast Company

Mar 18, 2025
pulisher
Mar 17, 2025

Partex and Fortress Biotech Announce Strategic - GlobeNewswire

Mar 17, 2025
pulisher
Mar 15, 2025

IO Biotech (NASDAQ:IOBT) Upgraded at Piper Sandler - Defense World

Mar 15, 2025
pulisher
Mar 13, 2025

Cancer Vaccines Market Analysis: Growth Drivers - openPR.com

Mar 13, 2025
pulisher
Mar 12, 2025

Bavarian Nordic A/S – Notice Convening Annual General Meeting - Finansavisen

Mar 12, 2025
pulisher
Mar 07, 2025

HC Wainwright Reiterates “Buy” Rating for IO Biotech (NASDAQ:IOBT) - Defense World

Mar 07, 2025
pulisher
Mar 07, 2025

Promising Clinical Developments and Delayed Data Boost IO Biotech’s Buy Rating - TipRanks

Mar 07, 2025
pulisher
Mar 06, 2025

Best Biotech Stocks to Buy in 2025 - The Motley Fool

Mar 06, 2025
pulisher
Mar 05, 2025

Ratio Chart Of U.S. Dollar Index Against 10Y U.S. Notes Is Pointing Much Lower - The Globe and Mail

Mar 05, 2025
pulisher
Mar 05, 2025

Melanoma Clinical Trials and Studies: EMA, PDMA, FDA Approvals, Mechanism of Action, ROA, NDA, IND, and Companies - The Globe and Mail

Mar 05, 2025
pulisher
Mar 05, 2025

Melanoma Clinical Trials and Studies: EMA, PDMA, FDA Approvals, - openPR

Mar 05, 2025
pulisher
Mar 05, 2025

BJ's (BJ) Q4 Earnings: What To Expect - The Globe and Mail

Mar 05, 2025
pulisher
Mar 05, 2025

Dollar Retreats on Growth Risk From US Tariffs - The Globe and Mail

Mar 05, 2025
pulisher
Mar 05, 2025

Metastatic Melanoma Pipeline 2024: Key Companies, MOA, ROA, - openPR

Mar 05, 2025
pulisher
Mar 05, 2025

IOBT To Report Melanoma Trial Data In Q3, NPCE Eyes 15-20% Revenue Growth For 2025, DXR On Watch - RTTNews

Mar 05, 2025
pulisher
Mar 05, 2025

IO Biotech on track with cancer vaccine BLA for 2025 By Investing.com - Investing.com Canada

Mar 05, 2025
pulisher
Mar 04, 2025

IO Biotech on track with cancer vaccine BLA for 2025 - Investing.com India

Mar 04, 2025
pulisher
Mar 04, 2025

IO Biotech Reports 2024 Business Highlights - The Manila Times

Mar 04, 2025
pulisher
Mar 04, 2025

IO Biotech Reports Progress on Cylembio® Development and Upcoming FDA Submission Plans - Nasdaq

Mar 04, 2025
pulisher
Mar 04, 2025

Cancer Vaccine Breakthrough? IO Biotech Accelerates Path to FDA Approval with Early Trial Completion - StockTitan

Mar 04, 2025
pulisher
Mar 03, 2025

The Search for the Next Keytruda: Immuno-Oncology’s Next Play - BioSpace

Mar 03, 2025
pulisher
Mar 02, 2025

5 Best Biotech Stocks To Watch (March 2025) - Securities.io

Mar 02, 2025
pulisher
Mar 02, 2025

IO Biotech (IOBT) to Release Quarterly Earnings on Tuesday - Defense World

Mar 02, 2025
pulisher
Mar 01, 2025

United States Steel: Buy, Sell, or Hold? - The Globe and Mail

Mar 01, 2025
pulisher
Feb 28, 2025

Pre-market Movers: BTAI, VRPX, DCGO, NBY... - RTTNews

Feb 28, 2025
pulisher
Feb 26, 2025

Metastatic Melanoma Clinical Trials and Pipeline 2025: EMA, - openPR

Feb 26, 2025
pulisher
Feb 24, 2025

Pre-market Movers: ISPC, TH, IVVD, TOVX... - RTTNews

Feb 24, 2025
pulisher
Feb 24, 2025

IO Biotech Announces New Preclinical Data for Additional Pipeline Candidate Presented at the AACR-IO Conference - The Manila Times

Feb 24, 2025
pulisher
Feb 24, 2025

Cellectis Presents ‘Smart CAR T’ Strategy to Enhance Efficacy Against Solid Tumors at AACR-IO 2025 - GlobeNewswire

Feb 24, 2025
pulisher
Feb 23, 2025

Artivion (AORT) Q4 Earnings: What To Expect - The Globe and Mail

Feb 23, 2025
pulisher
Feb 23, 2025

Should You Buy IonQ Stock Before Feb. 26? - The Globe and Mail

Feb 23, 2025
pulisher
Feb 23, 2025

IO Biotech Announces Positive Findings on TGF-β-Directed Peptide Vaccine for Solid Tumors at AACR-IO Conference - Nasdaq

Feb 23, 2025
pulisher
Feb 23, 2025

Can This New Cancer Vaccine Outsmart Tumors? IO Biotech's Breakthrough Approach - StockTitan

Feb 23, 2025
pulisher
Feb 23, 2025

32,667 Shares in IO Biotech, Inc. (NASDAQ:IOBT) Purchased by Vontobel Holding Ltd. - Defense World

Feb 23, 2025
pulisher
Feb 21, 2025

3 Reasons to Avoid SGH and 1 Stock to Buy Instead - The Globe and Mail

Feb 21, 2025
pulisher
Feb 20, 2025

IO Biotech to Present at the 45th Annual Cowen Health Care Conference - The Manila Times

Feb 20, 2025
pulisher
Feb 20, 2025

Can IO Biotech's Cancer Vaccine Pipeline Transform Immunotherapy? CEO Reveals Latest Progress - Stock Titan

Feb 20, 2025
pulisher
Feb 19, 2025

IO Biotech (NASDAQ:IOBT) Trading Up 4.2%Here's What Happened - MarketBeat

Feb 19, 2025
pulisher
Feb 19, 2025

Head and Neck Squamous Cell Carcinoma Market Analysis 2032: Clinical Trials, EMA, PDMA, FDA Approvals, Treatment Market, NDA Approval, Epidemiology and Companies by DelveInsight - Barchart

Feb 19, 2025

Io Biotech Inc Stock (IOBT) Financials Data

Revenue

loading

Net Income

loading

Cash Flow

loading

EPS

loading
$60.58
price down icon 3.01%
$69.18
price down icon 5.66%
$17.36
price down icon 8.20%
$31.11
price down icon 2.14%
$88.05
price down icon 4.30%
biotechnology ONC
$238.51
price down icon 9.76%
Cap:     |  Volume (24h):